L / RAIN
DESSAU, Germany – In the German city of Dessau, one of the sites of the Bauhaus School of Art, an institute was established in 1921 to mass produce vaccines that later helped the German Democratic Republic. ready to become a one-stop shop for producing COVID-19 vaccines for reaction to the German pandemic.
This is just one example of a number of efforts by governments around the world towards fragmented vaccine production, after production setbacks for disadvantaged EuS members of medicines manufactured on their own soil this year. reshape the industry.
The German company is supported by the regional government as a component of a national effort to protect materials and carry vaccines on German exports. Saxony-Anhalt’s Prime Minister Reiner Haseloff said he believed Germany could become a vaccine manufacturer of choice as a force, corporations maintain their capacity in times of peak demand.
“Ultimately, it’s comparable to the strength industry, where the state will also pay to keep power plants in reserve,” Haseloff said.
Unlike the United States, where the government’s Warp Speed operation began investing in the expansion and modernization of pharmaceutical production sites at the beginning of the pandemic, few countries in the world have the opportunity to seize factories. Dozens of governments around the world are scarcity by supporting local production of pharmaceutical companies.
Some, in addition to Australia, Brazil, Japan and Thailand, are building production partnerships with Swedish pharmacist AstraZeneca PLC. Elsewhere, Italy is committed to establishing a public-private vaccine production center, while Austria, Denmark and Israel are offering a joint fund of studies and progression and will explore the option of generating their own next-generation vaccines.
India plays a vital role in vaccine production globally, and the United States, Japan, and Australia also plan to fund vaccine production capacity in that country, a senior U. S. management official said.
These measures aim to address global dose shortages. Because vaccines are essential to revive economies, some countries have early purchase agreements to secure their supplies.
The vaccine crisis in Europe has shown that states with multinational deliveries can be vulnerable. In January, AstraZeneca cut its source to the bloc in more than a part for the first quarter and said in Brussels that it could not divert the Belgians. The cut has increased tensions between London and Brussels and led EU leaders to restrict exports of EU-made vaccines, starting this month, when Italy blocked exports of the AstraZeneca vaccine.
Germany is a net importer of all vaccines, with an industry deficit of $720 million in this area. Berlin plans to replace that, and the former “Anhalt County Bacteria Institute” in Germany in Dessau will contribute to this. family business called IDT Biologika, and AstraZeneca plan to invest more than one hundred million euros ($120 million) to expand the plant to a complete vaccine plant.
The corporation says it aims to manufacture between 30 million and 40 million doses consistent with the month from the end of 2022, by generating the vaccine in bulk and distributing it in vials, which, according to executive leader Juergen Betzing, would make it one of those in Europe. larger brands and capacity to create 360 million doses according to the EU year
Germany has not yet reserved the right to buy one of these vaccines, however, the government needs to expand a plan of measures and inspire long-term vaccine production capacity until May 1, according to a document noted through Reuters. Representatives of pharmaceutical corporations said in Berlin that long-term acquisition promises would be more vital to their investment decisions than aid.
The IDT plant will also produce vaccines for other corporations and, in combination with an organization of Saxony-Anhalt corporations, will form the focus of a government strategy to make Germany a new vaccine production center in Europe.
Berlin has an annual capacity of 2 billion doses of the IDT COVID vaccine and other facilities, according to a user close to the case. By comparison, AstraZeneca has expressed its ambitions to produce up to 3 billion doses of its vaccine by the end of this year, making it the world’s largest manufacturer of COVID-19 vaccines.
Berlin’s target may be well above the EU’s wishes for its 450 million inhabitants, but it is not yet known how vaccines will be needed to improve immunity.
The COVID-19 pandemic is an unprecedented challenge to inoculate billions. While drugs are painful in the short term, these one-on-one plans reflect the absence of a coherent global strategy for pandemic canopy immunization, which the world needs, according to Robert. Van Exan, Sanofi’s representative and former executive.
“It takes time to build this infrastructure properly, and we have to do it,” Van Exan said.
Previous disputes over vaccines between allies have served as a prelude to the COVID-era struggle.
In a 1976 influenza alert, the United States blocked vaccine exports, derailing a vaccination plan in Canada. Ottawa learned a lesson: the 2009 H1N1 pandemic bought medicines from a local manufacturer and waited until the outbreak ended before giving more doses to the country. World Health Organization.
And then, in the years after the 2009 pandemic, Washington paid heaps of millions of dollars to several corporations to build or expand personal services that could be used to manufacture and package a short-term pandemic vaccine within the country’s borders.
When COVID-19 hit, at least two of those sites were in Operation Warp Speed, generating vaccines for Johnson.
Globally, vaccines are manufactured in existing networks of pharmaceutical corporations and have to cross several countries, and even across continents, before they are in a position to be injected into weapons. In the EU alone, these are more than 30 plants from Sweden to Spain. coVID-19 vaccine production. AstraZeneca claims to have production capacity in 25 locations in 15 countries, in a chain of partnerships that a business leader compares to a Rubik’s Cube puzzle.
This is a similar symbol for others, adding vaccines manufactured across Russia and China, and disruptions are not unusual when looking to increase production at sites and borders. Lonza Group AG, founded in Switzerland, manufactures the ingredients for the Moderna vaccine, which are then sent to Spain for use in vials.
But friction between AstraZeneca and the EU in Brussels has continued to increase since a supplier from the drug manufacturer in Seneffe, Belgium, struggled in January.
Production of the AstraZeneca vaccine begins with infection of living cells with a change in the shape of the virus. The cells are grown in vats or bioreactors, collected and purified for approximately two months. Once the active element is created, water and proteins are added and the liquid is bottled, a step known as ” filling and finishing ”. Sometimes other stages occur elsewhere.
The disorders at the Belgian plant, combined with AstraZeneca’s contractual commitments to stock up in the UK, meant that even if the product involved was manufactured a few minutes’ drive from Brussels, EU citizens were left behind.
The German company IDT Biologika now plans to cover all stages of the cycle. Other German vaccines developed in line with BioNTech SE and CureVac NV, which are at the forefront of the new generation of vaccines and have won government funds, will also be part of the German initiative. Cluster. BioNTech recently introduced a new German plant to produce up to 750 million doses in line with the year and pharmaceutical giant Bayer AG will contribute to the implementation of CureVac.
Russian vaccine developers Sputnik V have asked about its production in the region, Saxony-Anhalt’s Prime Minister Haseloff said. Russia’s sovereign fund, the Russian Direct Investment Fund (DRIF), which promotes Sputnik V internationally, declined to comment.
AstraZeneca’s agreement with IDT is similar to other agreements the company has entered into, for example in Japan and Australia. Provisions like this also to reduce the threat to companies.
AstraZeneca declined to comment on the agreements, but one of its executives said in the afterlife that the company had sought to create chains from independent sources to allow the entire vaccine worldwide.
Strengthening vaccine production capacity makes sense given the desire to vaccinate the world, potentially repeatedly, as opposed to COVID-19, as well as the risk of long-term pandemics.
But giant production sites are the most effective and, at some point, greater capacity distributed in many countries may not be economical.
Prashant Yadav, lead researcher at the US-based Center for Global Development, is a U. S. -based global development researcher. U. S. , said the benefits of the scale multiply once at least one hundred million doses can be produced per year.
He thinks that probably four or five countries can grow without expanding costs, but if many build small operations, “I think we’ll get to a point where everyone will end up paying a higher price. “
In Canada, the federal government is building a public facility in Montreal that would produce about 2 million doses of vaccine in line with next year’s month, leaving it well below the $100 million annual dose threshold.
When asked whether the small length would increase costs, the National Research Council of Canada stated that it did not intend to compete with the personal sector: “The purpose of the facility is to respond temporarily to long-term fitness emergencies. “
At a time of incorrect information and too much information, quality journalism is more than ever.
Since the early stages of the COVID-19 crisis, the Japan Times has provided free access to very important data on the effect of the new coronavirus, as well as practical data on how to deal with the pandemic. today so that we can continue to provide you with up-to-date and detailed data on Japan.
Your subscription plan allows feedback. For more information, see our FAQs.
The Japan Times LTD. All rights are reserved.